

Petros Fessas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5971526/publications.pdf>

Version: 2024-02-01

36
papers

3,437
citations

430874

18
h-index

526287

27
g-index

37
all docs

37
docs citations

37
times ranked

3778
citing authors

#	ARTICLE	IF	CITATIONS
1	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	27.8	649
2	Immunotherapies for hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 151-172.	27.6	643
3	Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer. <i>JAMA Oncology</i> , 2019, 5, 1774.	7.1	396
4	The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 338-346.	3.7	299
5	A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. <i>Seminars in Oncology</i> , 2017, 44, 136-140.	2.2	183
6	A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI). <i>Journal of Hepatology</i> , 2012, 57, 1013-1020.	3.7	164
7	Immune-based therapies for hepatocellular carcinoma. <i>Oncogene</i> , 2020, 39, 3620-3637.	5.9	154
8	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. <i>Hepatology</i> , 2022, 76, 1000-1012.	7.3	114
9	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
10	Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. <i>Immunology</i> , 2020, 159, 167-177.	4.4	75
11	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.. , 2021, 9, e003311.		66
12	Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 2258-2270.	7.3	64
13	Validation of the Hepatoma Arterial Embolization Prognostic Score in European and Asian Populations and Proposed Modification. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1204-1208.e2.	4.4	53
14	Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 74, 483-490.	7.3	48
15	Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. <i>Cancers</i> , 2020, 12, 1862.	3.7	47
16	Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. , 2020, 8, e001033.		46
17	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
18	Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 55-61.	3.3	42

#	ARTICLE	IF	CITATIONS
19	Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. <i>European Journal of Cancer</i> , 2021, 157, 140-152.	2.8	42
20	Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 583-592.	7.7	33
21	Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma. <i>Liver International</i> , 2021, 41, 192-203.	3.9	32
22	Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. <i>Journal of Hepatology</i> , 2021, 75, 177-189.	3.7	29
23	Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. , 2022, 10, e004205.		26
24	Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. , 2020, 8, e000726.		21
25	Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2021, 111, 465-474.	2.5	15
26	Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110109.	3.2	15
27	Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2137.	3.7	11
28	Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 908-910.	7.0	11
29	Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2078-2082.	1.6	11
30	Evaluation of the sensitivity of R1 ρ -MRI to pH and macromolecular density. <i>Magnetic Resonance Imaging</i> , 2019, 58, 156-161.	1.8	7
31	Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. <i>Hepatology Communications</i> , 2022, 6, 1776-1785.	4.3	7
32	PD-L1 expressing granulomatous reaction as an on-target mechanism of steroid-refractory immune hepatotoxicity. <i>Immunotherapy</i> , 2019, 11, 585-590.	2.0	6
33	Question 1: Is there a role for the ketogenic diet in refractory status epilepticus?. <i>Archives of Disease in Childhood</i> , 2018, 103, 994.1-997.	1.9	2
34	Post-registration experience of nivolumab (nivo) therapy in patients with advanced hepatocellular carcinoma (HCC): An international study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16677-e16677.	1.6	1
35	Relationship between systemic inflammatory response markers and immune treatment related toxicity (IrAEs) in hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16204-e16204.	1.6	1
36	T α cell mediated responses against alpha α foetoprotein in hepatocellular carcinoma: Relationship with hepatitis C virus infection, tumour phenotype and patients α ™ survival. <i>Liver Cancer International</i> , 2021, 2, 7-14.	1.3	0